The reinfusion of perioperative cell salvage is one method employed to reduce exposure to donor blood. Data on the safety of this process, however, are scant. Notably, the effect of intraoperative, washed cell salvage reinfusion on prothrombotic markers has not been demonstrated. The risk of postoperative venous thromboembolism following major orthopaedic operations is not insignificant. The study objective was to assess the effect of cell salvage reinfusion on coagulation and platelet activation. Twenty-one patients undergoing elective primary hip operations were recruited. Nine patients received washed cell salvage intraoperatively, and were compared with 12 patients undergoing similar surgery that did not. Two patients in the cell salvage group also received postoperative, unwashed cell salvage. Blood samples were collected pre-operatively, immediately post-operatively, and one day post-operatively for assays of platelet activation markers, P-selectin expression and fibrinogen binding by flow cytometry in diluted whole blood; coagulation activation marker, thrombin-antithrombin complex (TAT); D-dimer by ELISA, thrombin generation by chromogenic assay, and full blood count. Samples of cell salvage material were also analysed for prothrombotic markers. There were no significant differences between the groups preoperatively. Postoperatively haemoglobin levels did not differ significantly between the cell salvage group and controls. Postoperative TAT and D-dimer were significantly higher in the cell salvage group compared with controls (p<0.05). One day postoperatively, there were significantly higher platelet P-selectin expression (p=0.006) and platelet fibrinogen binding (p=0.004) in the cell salvage group compared with controls. The white cell count (WCC) was also significantly higher (p=0.04). In the intraoperative washed cell salvage material, and in postoperative cell salvage, the platelet count was low, but significant proportions of platelets were activated, and levels of D-dimer were elevated compared with venous blood. The postoperative salvage material also contained high levels of TAT. The results from this pilot study show the induction of a prothrombotic state following reinfusion of intraoperative, washed cell salvage in recipients undergoing primary elective hip operations. An inflammatory response to reinfusion is also indicated by the raised WCC. Further investigation into the safety of cell salvage is indicated

Summary. There is emerging evidence of successful application of IOCS and leucocyte depletion filter in removing tumour cells from blood salvaged during various oncological surgeries. Research on the use of IOCS-LDF in MSTS is urgently needed. Introduction. Intra-operative cell salvage (IOCS) can reduce allogeneic blood transfusion requirements in non-tumour related spinal surgery. However, IOCS is deemed contraindicated in metastatic spine tumor surgery (MSTS) due to risk of tumour dissemination. Evidence is emerging from different surgical specialties describing the use of IOCS in cancer surgery. We wanted to investigate if IOCS is really contraindicated in MSTS. We hereby present a systematic literature review to answer the following questions: 1. Has IOCS ever been used in MSTS? 2. Is there any evidence to support the use of IOCS in other oncologic surgeries?. Methods. A systematic review of the English literature was conducted using computer searching of databases: Medline, Embase, the Cochrane Central Register of Controlled Trials for articles published between 1 January 1986 and 31 Dec 2012. Results. Question 1: A comprehensive literature search did not provide any publication describing the use of IOCS in MSTS. The application of IOCS in MSTS has never been described before. Question 2: Our systematic review shows that the use of IOCS has been extensively investigated in patients undergoing surgery for gynaecological, lung, urological, gastrointestinal, and hepatobiliary cancers. The literature review considered 281 abstracts from the initial search. After consideration by consensus, 30 articles were included in the final analysis. We included in our review -prospective, retrospective studies and in vitro studies. The selected articles were then classified according to the surgical specialty: gynaecological, lung, urological, gastrointestinal, and hepatobiliary cancers and type of studies: reinfusion studies, non-reinfusion studies and in vitro studies. 23 Reinfusion studies: Studies where salvaged blood was actually re-infused into patients and analyzed on the basis of clinical outcomes like survival, recurrence, metastasis rates, and transfusion requirements, etc. IOCS has been extensively investigated in several large cohort studies and large case series with considerable follow-up duration across urological, gynaecological, hepatobiliary and gastrointestinal cancers. Patients receiving salvaged blood have been shown to perform as well or better across a variety of clinical outcome measures as mentioned above. 2 in vitro studies and 5 non-reinfusion studies: Studies where salvaged blood was not re-infused into patients but was analyzed for the presence or viability of tumour cells in the processed blood. They consistently demonstrated the utility of LDF in either greatly reducing the number of tumour cells or even completely eradicating tumour cells from blood-tumour admixtures or salvaged blood. This provides the “proof-of-concept” that LDF is able and is effective in removing tumour cells from blood. Discussion/Conclusion. There is strong evidence that LDF can safely remove tumour cells from salvaged blood. IOCS in patients undergoing cancer surgery is not associated with any adverse clinical outcomes. The reluctance of spine surgeons to use IOCS in MSTS appears to be unsupported. There is ample evidence supporting the use of IOCS in oncological surgeries. Research is needed to evaluate the application of IOCS in MSTS